Blood, Cellular, and Tissular Calcineurin Inhibitors Pharmacokinetic-Pharmacodynamic Relationship in Heart Transplant Recipients: The INTRACAR Study.
Journal
Therapeutic drug monitoring
ISSN: 1536-3694
Titre abrégé: Ther Drug Monit
Pays: United States
ID NLM: 7909660
Informations de publication
Date de publication:
01 04 2023
01 04 2023
Historique:
received:
06
04
2022
accepted:
10
05
2022
pubmed:
26
8
2022
medline:
21
3
2023
entrez:
25
8
2022
Statut:
ppublish
Résumé
After heart transplantation, calcineurin inhibitors (CNI) (cyclosporin A and tacrolimus) are key immunosuppressive drugs to prevent graft rejection. Whole-blood concentration (C blood )-guided therapeutic drug monitoring (TDM) is systematically performed to improve graft outcomes. However, some patients will still experience graft rejection and/or adverse events despite CNI C blood within the therapeutic range. Other pharmacokinetic parameters, such as the intragraft, or intracellular concentration at the CNI site of action could refine their TDM. Nonetheless, these remain to be explored. The objective of the INTRACAR study was to describe the relationship between whole blood, intragraft, and intracellular CNI concentrations as well as their efficacy in heart transplant recipients (HTR). In a cohort of HTR, protocol endomyocardial biopsies (EMB) were collected to assess rejection by anatomopathological analysis. Part of the EMB was used to measure the intragraft concentrations of CNI (C EMB ). C blood and the concentration inside peripheral blood mononuclear cells, (C PBMC ), a cellular fraction enriched with lymphocytes, were also monitored. Concentrations in the 3 matrices were compared between patients with and without biopsy-proven acute rejection (BPAR). Thirty-four HTR were included, representing nearly 100 pharmacokinetic (PK) samples for each CNI. C blood , C EMB , and C PBMC correlated for both CNI. BPAR was observed in 74 biopsies (39.6%) from 26 patients (76.5%), all except one was of low grade. None of the PK parameters (C blood , C EMB , C PBMC , C EMB/blood , and C PBMC/blood ) was associated with BPAR. In this cohort of well-immunosuppressed patients, no association was observed for any of the PK parameters, including C blood , with the occurrence of BPAR. However, a trend was noticed for the C EMB and C EMB/blood of cyclosporin A. Further studies in higher-risk patients may help optimize the use of C EMB and C PBMC for CNI TDM in HTR.
Sections du résumé
BACKGROUND
After heart transplantation, calcineurin inhibitors (CNI) (cyclosporin A and tacrolimus) are key immunosuppressive drugs to prevent graft rejection. Whole-blood concentration (C blood )-guided therapeutic drug monitoring (TDM) is systematically performed to improve graft outcomes. However, some patients will still experience graft rejection and/or adverse events despite CNI C blood within the therapeutic range. Other pharmacokinetic parameters, such as the intragraft, or intracellular concentration at the CNI site of action could refine their TDM. Nonetheless, these remain to be explored. The objective of the INTRACAR study was to describe the relationship between whole blood, intragraft, and intracellular CNI concentrations as well as their efficacy in heart transplant recipients (HTR).
METHODS
In a cohort of HTR, protocol endomyocardial biopsies (EMB) were collected to assess rejection by anatomopathological analysis. Part of the EMB was used to measure the intragraft concentrations of CNI (C EMB ). C blood and the concentration inside peripheral blood mononuclear cells, (C PBMC ), a cellular fraction enriched with lymphocytes, were also monitored. Concentrations in the 3 matrices were compared between patients with and without biopsy-proven acute rejection (BPAR).
RESULTS
Thirty-four HTR were included, representing nearly 100 pharmacokinetic (PK) samples for each CNI. C blood , C EMB , and C PBMC correlated for both CNI. BPAR was observed in 74 biopsies (39.6%) from 26 patients (76.5%), all except one was of low grade. None of the PK parameters (C blood , C EMB , C PBMC , C EMB/blood , and C PBMC/blood ) was associated with BPAR.
CONCLUSIONS
In this cohort of well-immunosuppressed patients, no association was observed for any of the PK parameters, including C blood , with the occurrence of BPAR. However, a trend was noticed for the C EMB and C EMB/blood of cyclosporin A. Further studies in higher-risk patients may help optimize the use of C EMB and C PBMC for CNI TDM in HTR.
Identifiants
pubmed: 36006706
doi: 10.1097/FTD.0000000000001025
pii: 00007691-202304000-00014
doi:
Substances chimiques
Calcineurin Inhibitors
0
Cyclosporine
83HN0GTJ6D
Immunosuppressive Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
229-235Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Khush KK, Hsich E, Potena L, et al. The international thoracic organ transplant registry of the international society for heart and Lung transplantation: thirty-eighth adult heart transplantation report—2021; focus on recipient characteristics. J Heart Lung Transpl. 2021;40:1035–1049.
Chih S, Chong AY, Mielniczuk LM, et al. Allograft vasculopathy: the achilles' heel of heart transplantation. J Am Coll Cardiol. 2016;68:80–91.
Brunet M, van Gelder T, Åsberg A, et al. Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report. Ther Drug Monit.2019;41:261–307.
Furiasse N, Kobashigawa JA. Immunosuppression and adult heart transplantation: emerging therapies and opportunities. Expert Rev Cardiovasc Ther. 2017;15:59–69.
Bentata Y. Tacrolimus: 20 years of use in adult kidney transplantation. What we should know about its nephrotoxicity. Artif Organs. 2020;44:140–152.
Lemaitre F, Antignac M, Fernandez C. Monitoring of tacrolimus concentrations in peripheral blood mononuclear cells: application to cardiac transplant recipients. Clin Biochem. 2013;46:1538–1541.
Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet. 2004;43:623–653.
Sandborn WJ, Lawson GM, Cody TJ, et al. Early cellular rejection after orthotopic liver transplantation correlates with low concentrations of FK506 in hepatic tissue. Hepatology. 1995;21:70–76.
Capron A, Lerut J, Verbaandert C, et al. Validation of a liquid chromatography-mass spectrometric assay for tacrolimus in liver biopsies after hepatic transplantation: correlation with histopathologic staging of rejection. Ther Drug Monit. 2007;29:340–348.
Capron A, Mourad M, De Meyer M, et al. CYP3A5 and ABCB1 polymorphisms influence tacrolimus concentrations in peripheral blood mononuclear cells after renal transplantation. Pharmacogenomics. 2010;11:703–714.
Francke MI, Hesselink DA, Li Y, et al. Monitoring the tacrolimus concentration in peripheral blood mononuclear cells of kidney transplant recipients. Br J Clin Pharmacol. 2021;87:1918–1929.
Capron A, Lerut J, Latinne D, et al. Correlation of tacrolimus levels in peripheral blood mononuclear cells with histological staging of rejection after liver transplantation: preliminary results of a prospective study. Transpl Int. 2012;25:41–47.
Lepage JM, Lelong-Boulouard V, Lecouf A, et al. Cyclosporine monitoring in peripheral blood mononuclear cells: feasibility and interest. A prospective study on 20 renal transplant recipients. Transpl Proc. 2007;39:3109–3110.
Falck P, Asberg A, Guldseth H, et al. Declining intracellular T-lymphocyte concentration of cyclosporine a precedes acute rejection in kidney transplant recipients. Transplantation. 2008;85:179–184.
Lemaitre F, Blanchet B, Latournerie M, et al. Pharmacokinetics and pharmacodynamics of tacrolimus in liver transplant recipients: inside the white blood cells. Clin Biochem. 2015;48:406–411.
Capron A, Haufroid V, Wallemacq P. Intra-cellular immunosuppressive drugs monitoring: a step forward towards better therapeutic efficacy after organ transplantation?. Pharmacol Res. 2016;111:610–618.
Roullet-Renoleau F, Lemaitre F, Antignac M, et al. Everolimus quantification in peripheral blood mononuclear cells using ultra high performance liquid chromatography tandem mass spectrometry. J Pharm Biomed Anal. 2012;66:278–281.
Stewart S, Winters GL, Fishbein MC, et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transpl. 2005;24:1710–1720.
Lemaitre F, Vethe NT, D'Avolio A, et al. Measuring intracellular concentrations of calcineurin inhibitors: expert consensus from the international association of therapeutic drug monitoring and clinical toxicology expert panel. Ther Drug Monit. 2020;42:665–670.
Roussel M, Benard C, Ly-Sunnaram B, Fest T. Refining the white blood cell differential: the first flow cytometry routine application. Cytometry A. 2010;77:552–563.
Tron C, Coste G, Lalanne S, et al. A simple and fast liquid chromatography tandem mass spectrometry method to determine cyclosporine A concentrations in endomyocardial biopsies. J Pharm Biomed Anal. 2021;193:113664.
Noll BD, Coller JK, Somogyi AA, et al. Measurement of cyclosporine A in rat tissues and human kidney transplant biopsies-a method suitable for small (<1 mg) samples. Ther Drug Monit. 2011;33:688–693.
Noll BD, Coller JK, Somogyi AA, et al. Validation of an LC-MS/MS method to measure tacrolimus in rat kidney and liver tissue and its application to human kidney biopsies. Ther Drug Monit. 2013;35:617–623.
Krogstad V, Vethe NT, Robertsen I, et al. Determination of tacrolimus concentration and protein expression of P-glycoprotein in single human renal core biopsies. Ther Drug Monit. 2018;40:292–300.
Zhang M, Tajima S, Shigematsu T, et al. Development and validation of A liquid chromatography-tandem mass spectrometry method to simultaneously measure tacrolimus and everolimus concentrations in kidney allograft biopsies after kidney transplantation. Ther Drug Monit. 2022;44:275–281.
Sallustio BC, Noll BD, Hu R, et al. Tacrolimus dose, blood concentrations and acute nephrotoxicity, but not CYP3A5/ABCB1 genetics, are associated with allograft tacrolimus concentrations in renal transplant recipients. Br J Clin Pharmacol. 2021;87:3901–3909.
Bodnar-Broniarczyk M, Durlik M, Bączkowska T, et al. Kidney and liver tissue tacrolimus concentrations in adult transplant recipients-the influence of the whole blood and tissue concentrations on efficiency of treatment during immunosuppressive therapy. Pharmaceutics. 2021;13:1576.
Sandborn WJ, Lawson GM, Krom RA, Wiesner RH. Hepatic allograft cyclosporine concentration is independent of the route of cyclosporine administration and correlates with the occurrence of early cellular rejection. Hepatology. 1992;15:1086–1091.
Robertsen I, Falck P, Andreassen AK, et al. Endomyocardial, intralymphocyte, and whole blood concentrations of ciclosporin A in heart transplant recipients. Transpl Res. 2013;2:5.
Molinaro M, Pellegrini C, Cattadori B, De Gregori S. Development and validation of a combined enzymatic-digestion/mass spectrometry assay for Tacrolimus quantitation in cardiac biopsies. J Chromatogr B Analyt Technol Biomed Life Sci. 2020;1152:122215.
Available at: https://www.ema.europa.eu/en/bioanalytical-method-validation . Accessed March 23, 2022.
Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007;357:2562–2575.
Udomkarnjananun S, Francke MI, De Winter BCM, et al. Therapeutic drug monitoring of immunosuppressive drugs in hepatology and gastroenterology. Best Pract Res Clin Gastroenterol. 2021;54-55:101756.